{"id":"nnc0487-0111","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Gastrointestinal disorders"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By simultaneously activating GLP-1 and GIP receptors, this dual agonist enhances insulin secretion in response to glucose, slows gastric emptying, and increases satiety signals in the brain. This dual mechanism produces greater metabolic benefits than single GLP-1 agonists, resulting in improved blood glucose control and significant weight reduction in patients with type 2 diabetes and obesity.","oneSentence":"NNC0487-0111 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:18.987Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management"}]},"trialDetails":[{"nctId":"NCT07481630","phase":"PHASE3","title":"A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-04-13","conditions":"Obesity, Knee Osteoarthritis (OA)","enrollment":400},{"nctId":"NCT07400107","phase":"PHASE3","title":"AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-05-20","conditions":"Obesity, Overweight, Diabetes Mellitus, Type 2","enrollment":1000},{"nctId":"NCT07339423","phase":"PHASE3","title":"AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-02-24","conditions":"Obesity","enrollment":1150},{"nctId":"NCT07121153","phase":"PHASE1","title":"A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2025-08-11","conditions":"Overweight, Obesity","enrollment":36},{"nctId":"NCT06542874","phase":"PHASE2","title":"A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-08-07","conditions":"Type 2 Diabetes (T2D)","enrollment":448},{"nctId":"NCT06064006","phase":"PHASE2","title":"A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-15","conditions":"Obesity, Overweight","enrollment":125},{"nctId":"NCT06820476","phase":"PHASE1","title":"A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2025-02-09","conditions":"Overweight, Obesity","enrollment":29},{"nctId":"NCT06478563","phase":"PHASE1","title":"A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-06-27","conditions":"Obesity, Overweight","enrollment":133},{"nctId":"NCT05369390","phase":"PHASE1","title":"A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-05-11","conditions":"Obesity","enrollment":144},{"nctId":"NCT06461039","phase":"PHASE1","title":"A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-06-14","conditions":"Obesity","enrollment":43},{"nctId":"NCT06559527","phase":"PHASE1","title":"A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-08-20","conditions":"Diabetes Mellitus, Type 2, Obesity, Overweight","enrollment":42},{"nctId":"NCT06049329","phase":"PHASE1","title":"A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-14","conditions":"Obesity","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NNC0487-0111","genericName":"NNC0487-0111","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NNC0487-0111 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}